We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+10.92%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$355M
AUM Growth
-$16.8M
Cap. Flow
-$17.7M
Cap. Flow %
-4.99%
Top 10 Hldgs %
50.26%
Holding
90
New
4
Increased
16
Reduced
25
Closed
11

Top Buys

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$9.25M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$4.36M
3
BHVN icon
Biohaven
BHVN
+$3.33M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$3.13M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$2.14M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$16.6M
2
CBAY
Cymabay Therapeutics
CBAY
+$5.82M
3
ACET icon
Adicet Bio
ACET
+$4.74M
4
AERI
Aerie Pharmaceuticals
AERI
+$4.65M
5
ETNB
89bio
ETNB
+$2.98M

Sector Composition

Rank Sector Weight
1 Healthcare 81.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBAY
51
DELISTED
Cymabay Therapeutics
CBAY
$1.07M 0.3%
171,059
-1,532,176
-90% -$5.82M
SYRS
52
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$955K 0.27%
265,878
– –
GNFT
53
DELISTED
Genfit
GNFT
$869K 0.24%
197,940
+10,000
+5% +$38.6K
AFMD
54
DELISTED
Affimed
AFMD
$851K 0.24%
68,628
– –
MREO
55
Mereo BioPharma
MREO
$47.3M
$822K 0.23%
1,096,513
– –
PRDS
56
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$810K 0.23%
479,386
– –
RGLS
57
DELISTED
Regulus Therapeutics
RGLS
$761K 0.21%
555,555
– –
KPTI icon
58
Karyopharm Therapeutics
KPTI
$48M
$655K 0.18%
+12,845
New +$890K
SURF
59
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$642K 0.18%
783,000
-317,000
-29% -$313K
CINC
60
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$590K 0.17%
+48,000
New +$1.14M
BWAY
61
Brainsway
BWAY
$622M
$543K 0.15%
440,000
– –
ADAP
62
DELISTED
Adaptimmune Therapeutics
ADAP
$513K 0.14%
351,064
– –
MASI
63
DELISTED
Masimo
MASI
$444K 0.13%
3,000
– –
KNTE
64
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$433K 0.12%
71,008
-7,066
-9% -$57.5K
THRX
65
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$408K 0.11%
81,859
-40
-0% -$234
IMA
66
ImageneBio Inc
IMA
$64.6M
$326K 0.09%
10,210
– –
MDNA
67
DELISTED
Medicenna Therapeutics Corp. Common Shares
MDNA
$302K 0.09%
660,000
– –
INGN icon
68
Inogen
INGN
$164M
$296K 0.08%
15,000
– –
BMEA icon
69
Biomea Fusion
BMEA
$91.3M
$292K 0.08%
34,625
– –
MGNX icon
70
MacroGenics
MGNX
$257M
$268K 0.08%
39,879
-60,121
-60% -$330K
NXTC icon
71
NextCure
NXTC
$23.8M
$265K 0.07%
15,641
– –
SCYX icon
72
SCYNEXIS
SCYX
$52M
$239K 0.07%
19,159
-30,724
-62% -$543K
SPRO icon
73
Spero Therapeutics
SPRO
$73M
$216K 0.06%
125,000
– –
ACRV icon
74
Acrivon Therapeutics
ACRV
$74M
$180K 0.05%
+15,648
New +$199K
BDTX icon
75
Black Diamond Therapeutics
BDTX
$112M
$176K 0.05%
97,500
-216,100
-69% -$389K
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return
BCM
Beck Capital Management Austin, Texas $437M AUM 59.35% 1-Year Est. Return

DAFNA Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, DAFNA Capital Management held 90 positions worth $355M, down 4.5% from $372M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

DAFNA Capital Management withdrew a net $17.7M in Q4 2022, closing 11 positions and reducing 25 holdings. Its most notable exit was Biohaven Pharmaceutical Holding Company Ltd., an estimated $16.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 82% a quarter earlier.

Against the trend, DAFNA Capital Management opened a new position in BioCryst Pharmaceuticals worth $2.88M.

  • DAFNA Capital Management's largest Q4 2022 buy was BioCryst Pharmaceuticals: 251,000 shares worth $2.88M.
  • DAFNA Capital Management added most to Karuna Therapeutics, Inc. Common Stock in Q4 2022, an estimated $9.25M increase.
  • DAFNA Capital Management's biggest Q4 2022 reduction was Cymabay Therapeutics, cutting an estimated $5.82M.
  • DAFNA Capital Management fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q4 2022, selling an estimated $16.6M.
  • DAFNA Capital Management's ten largest holdings make up 50% of its $355M portfolio in Q4 2022.
  • DAFNA Capital Management opened 4 new positions and closed 11 in Q4 2022.
  • DAFNA Capital Management's portfolio value fell 4.5% quarter-over-quarter to $355M.

Based on DAFNA Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.